Notes

The trading plan starts at 02:00:50UTC and has a 37-minute budget, with 12 minutes for discovery, 10 minutes for primary and economics review, 10 minutes for testing, and 5 minutes to finish, with a hard stop at 45 minutes. The plan assumes there are no new eligible names due to prior negative events. The discovery process has three parts: A1, which reviews the US universe for listing completeness, date coverage, and affordable liquidity; A2, which looks at overseas markets for local-language issuer calendars, ADR mapping, and FX/venue; and A3, which examines crypto markets for actual dated issuer events, cash capture, and mandate fit. The catalyst verification process, B, has three parts: B1, which verifies earnings by comparing the first release to the call, checking for early preannouncements, and reviewing historical dates; B2, which checks FDA deadlines, earliest decisions, and competing pipelines; and B3, which reviews economics, including cash versus adjusted profit, financing, and per-share valuation. The edge analysis, C, has three parts: C1, which reviews the ledger for censoring, winner/loss samples, and gaps; C2, which backtests the strategy using frozen entry and exit points, chronological out-of-sample testing, and fees/slippage; and C3, which assesses feasibility, including a full-share cap of 49.14, risk of 8.5099, and 15-minute exits. The handoff process, D, has three parts: D1, which collects actual footers, errors, and fresh sources; D2, which monitors due dates, including 155 and next 04UTC, and preserved 137/22; and D3, which concludes with premises, counterexamples, quarter Kelly, and cash. The plan uses daily price resolution and exact primary event dates, and discards wealth headlines and unverified estimated dates. There are no holdings in the supplied context, and the binding constraint is a positive, independently measured, executable edge.

The Catalyst Research fund has the following updates as of September 10, 2026, at 01:15:41 UTC. The fund is tracking several companies, including Telix Pharma, which will present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference on September 9, 2026. Mission Produce announced its fiscal 2026 third-quarter financial results on September 8, 2026. ABM reported its fiscal third-quarter 2026 results on September 8, 2026. Roivant announced positive results from the Phocus study of mosliciguat on September 8, 2026. The fund also reviewed SEC filings from UNFI, DRI, PPIH, MRK, and WLTH. Additionally, the fund checked the websites of Kingfisher and Askul, which returned HTTP200 status codes, indicating that the websites are functioning properly. The fund has scheduled reviews for the following dates and times: AVO and PPIH on September 9 at 12:30, WLTH and TLX on September 10 at 12:30, Askul on September 15, MRK on September 18, KGF on September 22, and DRI on September 24. The fund does not have any automatic orders in place and will follow a strong cash and data validation process, which involves recording and validating data, and a weak or absent cash and reverification process, which involves cash and reverifying data.

The fund is called Catalyst Research and it has no size. The current time is 2026-09-10T01:00:54.392165+00:00 in UTC time, which is a way to show the time in a standard format. There are some updates about the stocks SRRK, SCHL, and PRAX. On September 2, 2026, SRRK, which is Scholar Rock, received a special designation from the FDA, which is a US government agency that approves new medicines. This designation is called Fast Track and it helps the development of new medicines. On August 27, 2026, SRRK announced that it will present at upcoming investor conferences, which are meetings where companies talk to investors about their business. On August 21, 2026, SRRK provided an update on its medicine called Apitegromab, which is being developed to treat a disease. On September 3, 2026, SCHL, which is Scholastic Corporation, announced the date for its first quarter fiscal 2027 results. On September 3, 2026, PRAX, which is Praxis Precision Medicines, Inc., announced that it gave some grants to its employees. The SEC, which is a US government agency that regulates the stock market, has a filing from SRRK on August 6, 2026. The fund will review SRRK on September 9, September 10, and September 29 before September 30. It will also review SCHL on September 24 and September 25, and PRAX on December 27. The fund will make decisions based on the data it receives. If the data is favorable, it will record the results and validate them independently. If the data is adverse, delayed, or absent, it will use cash or reverify the results. The fund will not enter the market automatically and the reminders are not exact execution times. The fund has 3 SRRK stocks, 1 SCHL stock, and 1 PRAX stock, and it uses an RSS feed, which is a way to get news updates, and the SEC, but this is not an exhaustive list.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 10, 2026, at 01:00:51 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, and ASO's 10-Q filing on September 9, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/1766502/000162828026061018/chwy-20260802.htm and https://www.sec.gov/Archives/edgar/data/1817358/000181735826000149/aso-20260801.htm, respectively. The manager also reviewed LOVE's 8-K filing on June 15, 2026, and SFIX's 8-K filing on July 28, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/1701758/000121390026068869/ea0294793-8k_lovesac.htm and https://www.sec.gov/Archives/edgar/data/1576942/000162828026050133/sfix-20260722.htm, respectively. Additionally, the manager reviewed the following RSS feeds: SAIL's announcement on September 9, 2026, at 07:00:50 -0400, which can be found at https://investor.sailpoint.com/news-releases/news-release-details/sailpoint-announces-fiscal-second-quarter-2027-results, and KFY's announcement on September 9, 2026, at 06:45:00 -0400, which can be found at https://ir.kornferry.com/news-events/press-releases/detail/733/korn-ferry-announces-first-quarter-fiscal-2027-results-of-operations. The manager also reviewed LOVE's press release on August 27, 2026, at 07:00:00 -0400, which can be found at https://investor.lovesac.com/news-events/press-releases/detail/166/the-lovesac-company-announces-second-quarter-conference. Furthermore, the manager reviewed GRAL's FDA update, which can be found at https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting. The manager noted that the SEC filings may lag behind news and that reviews will take place on September 9 at 12:30 for new morning results, on September 10 at 12:30 for LOVE, and on September 24 at 12:30 for SFIX after the September 23 AMC. The manager also noted that GRAL's September 23 panel is not an approval. The manager will preserve cash for strong results and reverify weak or early results. No automatic orders were placed.

A run began at 00:00:53 and finished around 00:05 UTC, which is within the allowed 31 minutes and the hard limit of 45 minutes. The journal phase took 00:02:51. There were 18628 to 33 observations and 1803 to 07 analyses, plus strategy and 3 lessons saved. The KFY extra on September 9, 8-K000033, is a segment recast, not a consolidated cash change. The AVO manual RSS was recovered with the latest results from September 8, which showed a 9-month free cash flow of -57.9 million, and the Q4 EBITDA guide requires 60.49 to 69.75 percent sequential growth, but this is affected by seasonality and the full Calavo confound. There are no holdings and no proposals, with 49.14 in cash. The Due 153 was resolved, and the next AVO research monitors are armed for October 2 and 8. The 137 LOVE and 22 TLX were preserved. Five collectors were retained, with checks at actual times. The LOVE historical holdout is separate from the N1 paper win, and the AVO holdout is negative, with a quarter Kelly of 0. There are gaps in the data, including post-AMScash, full TLX pipeline, earliest news, and AVO agenda 403, and the broad market search was not exhaustive. No new price or valuation or strategy validation is claimed. The initial 3-minute commentary was overestimated and corrected to 2 minutes, with actual timestamps controlling the analysis. The analysis 1804 text '=0.3 frozen' means '=0; premise 3 frozen', not Kelly 0.3, and the figures are correctly 0.

The plan starts at 00:00:53 UTC and allows 31 minutes, including a final 5 minutes, with a hard stop at 45 minutes. Previous failures suggest that new disclosures may not add value, so cash will be set aside. New information includes: A1, a retry of the timeout for AVO, looking at original results and the connection between cash and volume; A2, examining all changes in form for KFY and ASO, including period cash and financing; and A3, looking at biotech company TLX, making an early decision based on the full pipeline and source timing. The attack theses are: B1, examining organic demand and refund dependence for LOVE; B2, looking at acquisition and refund recipients, recurring cash, and per-share burden; and B3, considering broader dates, including US and non-US calendars, confirmed releases versus calls, and affordable venues. The edge is: C1, examining the company's own ledger for censoring, gap loss, and stop execution; C2, looking at frozen holdouts, including sample, costs, and uncertainty; and C3, implementing whole shares, 1% equity risk, and pre-event exit. The handoff includes the actual collector footer, monitoring 153, and next actions at 02UTC. The goal is to achieve repeatable pre-event gains, with a binding constraint of independently positive executable edge, and quarterly cash and dated primary releases will be used, while retrospective wealth headlines will be discarded as entry evidence. There are currently no holdings or pending orders according to the queried ledger.

The Catalyst fund is currently researching IONS, MIRM, and GIS, with a size of 0, as of September 9, 2026, at 22:45:41 UTC. The fund has reviewed SEC filings from IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. On September 9, 2026, Barclays maintained an overweight rating on Ionis Pharmaceuticals, lowering its price target to $85. GIS had a conference on September 8, 2026, at 19:00 UTC, which has already passed. The fund will review GIS's earnings on September 23, 2026, at 13:00 UTC. For GIS, stronger organic cash flow will be recorded and validated, while weaker or absent cash flow will require re-verification. The baseline for GIS's FY27 EPS is $3.00-3.20, with organic growth of -1.5% to +0.5% and savings of $750 million. EAT will have an investor day on September 17, 2026, and an earnings call on October 28, 2026. The fund will review EAT's earnings on October 28, 2026, at 16:30 UTC. For EAT, stronger organic cash flow will be recorded and validated, while weaker or absent cash flow will require re-verification. The fund has four SEC filings, one discovery, and two reviews for GIS and EAT, and will verify full pipelines and early news.

The automated trading fund manager completed the handoff at 00:00, resulting in a win for the LOVE paper. There were new cash filings, but no proposals. The Run21:01:30-21:06UTC, which lasted approximately 5 minutes, was within the 28-minute allowance and 45-minute hard limit. The final records phase began at 21:04. There were no proposals, with $49.14 in cash and no open or pending items. The manager made 1801 decisions, 1787 technical assessments, 1788 fundamental assessments, 1789 statistical analyses, and reused 1791 simulations to evaluate consequences. Observations were made from 18618 to 18624, and lessons were learned from 570 to 572. The LOVE paper opened at $15.87 at 13:30 and closed at $16.15 at 19:45, with a net gain of 1.414575% and stress of 1.211948%. The N1 prospective was separate from the 1677 N10 stress of -2.341352%. The manager analyzed 26 regular 15-minute bars, discarding those inclusive of 20 UTC, and noted no auction close or real fill. The ASO new Sep 9 10Q gross refund was $83.7 million, and the Q2 remit was $72.2 million, which was resolved. The estimated gross free cash flow was approximately $153.858 million before tax and interest normalization. The KFY new Sep 9 10Q operating cash flow was -$247.630 million, with $634 million in debt for AMS and approximately $0.3 billion in cash on hand. The exact post-closing cash amount is unknown. The manager corrected prior unknowns rather than repeating stale notes from 19:40. The 149 issues were resolved, and 153 were next armed at 00. The 137 LOVE and 22 TLX positions were preserved. The existing 5 jobs remained unchanged, and the manager inspected the 12622:31 actual footer at 00. The 75/132 20:46 and 138 21:01 footers were full. An AVO read timeout occurred, which is a gap, and a manual retry will be attempted at the next research session. The SEC direct requests worked, while the web open failed. A stdlib parser fallback was used after the bs4 missing/local reerror, and the downloaded HTML was used successfully. No strategy refit or new backtest was needed for the failed gate. The sources are in 1788/18618-24, and there were no other fund actions.

The trading review started at 21:01 with a 28-minute time allowance, including a final 5 minutes, and a hard stop at 21:01:30 UTC. Previously, failed holdouts implied zero entry, and the expectation was set aside that new disclosures would add nothing. There were uncertainties to consider, including three areas: A1, regarding ASO's new 10Q report, which would reveal gross refunds, Q2 remittances, and period bridge information; A2, regarding KFY, which would involve correct CIK, full OCF, and post-AMS funding; and A3, regarding collectors, which would involve actual payload, errors versus absence, and early news. The review also considered paper execution, including three areas: B1, frozen1677, which involved entry and exit timestamp convention, fees, and stop cadence; B2, SIP, which involved all intervals, time exit, and benchmark; and B3, calendar, which involved LOVE primary date, early release, and overnight exposure. The decision-making process involved three areas: C1, edge, which considered out-of-sample data, costs, and selection; C2, constraints, which involved ledger and capital, Kelly, and loss limit; and C3, handoff, which involved due149, existing137, and next00UTC. The resolution was completed within 15 minutes, and quarterly cash was considered. The goal was to achieve repeatable pre-event gain with an independent executable edge, and the binding constraint was to have a repeatable process.

The fund is called Catalyst Research and it is used for research only. The size of the fund is 0 and the time is 2026-09-09T21:01:13.892658+00:00. There are several news updates: TLX will present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 9, 2026, at 10:30:00 +0000, which can be found at https://telixpharma.com/news-views/telix-to-present-at-the-morgan-stanley-24th-annual-global-healthcare-conference-and-h-c-wainwright-28th-annual-global-investment-conference/. There was an error reading the news from AVO due to a ReadTimeout at https://investors.missionproduce.com/rss/news-releases.xml. ABM reported its fiscal third quarter 2026 results on Tuesday, September 8, 2026, at 06:58:07 -0400, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results. ROIV announced positive results from the Phocus study of mosliciguat on Tuesday, September 8, 2026, at 06:00:31 -0400, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. There are also several SEC filings: UNFI filed an 8-K on September 8, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/1020859/000102085926000022/unfi-20260903.htm, DRI filed a 10-K on July 24, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/940944/000094094426000025/dri-20260531.htm, PPIH filed a 10-Q on September 9, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/914122/000143774926029988/ppih20260731_10q.htm, MRK filed a 10-Q on August 7, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm, and WLTH filed an 8-K on September 9, 2026, which can be found at https://www.sec.gov/Archives/edgar/data/1524566/000162828026061131/wlth-20260909.htm. The HTTP requests to KGF and ASKUL were successful, with hashes dda88bf6ef8ad8058f930e800995fe79f40d67d7f920c6142787f79c562ab26b and e6f0d85c03a37ce688343d47b65221e2fdee30a5480ab1e61b906eaf45433ff6, respectively. The reviews are scheduled as follows: AVO and PPIH on September 9 at 12:30, WLTH and TLX on September 10 at 12:30, ASKUL on September 15, MRK on September 18, KGF on September 22, and DRI on September 24. The full dates and branches are noted in notes 1299 and 1308. There are no automatic orders. The cash and data are considered strong if they are recorded and validated, and weak or absent if they need to be reverified.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 9, 2026, at 20:46:07 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, available at https://www.sec.gov/Archives/edgar/data/1766502/000162828026061018/chwy-20260802.htm, ASO's 10-Q filing on September 9, 2026, available at https://www.sec.gov/Archives/edgar/data/1817358/000181735826000149/aso-20260801.htm, LOVE's 8-K filing on June 15, 2026, available at https://www.sec.gov/Archives/edgar/data/1701758/000121390026068869/ea0294793-8k_lovesac.htm, and SFIX's 8-K filing on July 28, 2026, available at https://www.sec.gov/Archives/edgar/data/1576942/000162828026050133/sfix-20260722.htm. The manager also reviewed the following RSS feeds: SAIL's announcement on September 9, 2026, at 07:00:50 -0400, available at https://investor.sailpoint.com/news-releases/news-release-details/sailpoint-announces-fiscal-second-quarter-2027-results, KFY's announcement on September 9, 2026, at 06:45:00 -0400, available at https://ir.kornferry.com/news-events/press-releases/detail/733/korn-ferry-announces-first-quarter-fiscal-2027-results-of-operations, and LOVE's announcement on August 27, 2026, at 07:00:00 -0400, available at https://investor.lovesac.com/news-events/press-releases/detail/166/the-lovesac-company-announces-second-quarter-conference. Additionally, the manager reviewed an FDA update, which included a meeting on September 23, 2026, available at https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting. The manager noted that SEC filings may lag behind news and scheduled reviews for September 9 at 12:30, September 10 at 12:30 for LOVE, and September 24 at 12:30 for SFIX after the AMC on September 23. The manager also noted that GRAL's panel on September 23 is not an approval. The manager will prioritize strong cash positions, requiring record and validation, while weak or early positions will require cash and re-verification. No automatic orders were placed.

The fund, called Catalyst Research, made notes on September 9, 2026, at 20:46:07 UTC. It looked at SEC filings from HITI on August 31, 2026, and BFRI on August 13, 2026. The fund also noted that Dave & Buster’s Entertainment, Inc., ticker symbol PLAY, would report its second-quarter results on September 1, 2026. The fund has a list of static reviews, which are not guaranteed to be released or delivered on time, including TSM on September 10, DATA.L on September 14, and others. It also has a list of new reviews, including CAN on September 8, PLAY on September 15, and EGTX on September 25. The fund made decisions based on organic cash and clinical evidence, and it did not make any automatic orders. It rejected a decision to hold out on PLAY with a confidence interval of -4.48% to 7.25%. The fund also made an early decision on EGTX, which is not bounded by a stop. The fund uses a system called MFN, which stands for a type of financial data feed, to track EGTX, and it has 48 entries with a hash of 85e339a790c3. The fund will review EGTX on September 11 and 16, and again on September 25 before the FDA decision on September 28. If there is a new label, PRV, or cash, the fund will record and validate it, and if there is adverse or delayed news, it will stay in cash and reverify. The fund has static reminders, but they are not armed, meaning they will not automatically make trades.

The automated trading fund manager reported that between 19:41:14 and 19:46 UTC, about 5 minutes, the system was active, which is shorter than the planned 32 minutes and the hard limit of 45 minutes. The final recording started at 19:44. There were no proposals, and the cash on hand was $49.14. The manager analyzed data from 1775 to 1779, as well as the final strategy, and made observations from 18591 to 18596, and noted lessons from 561 to 563. The manager reported that 144 issues were resolved, with 149 to be addressed next at 21:00. The LOVE stock's final paper exit was pending due to delayed data, with an entry price of $15.87 and an ADR of $15.21, a stop price of $15.21, and a target price of $16.85, with original costs of $1677. The last 23 checks were completed through the 19:00 start, with an open price of $16.12, which represented a gain of 1.5753%. The manager noted that the ASO's latest 10Q report was from June 10, and that $165.334 million was retained, compared to distributions of $199.461 million. The KFYCIK report from September 1 showed $473 million in GBP and $326 million in USD, with 3118628 shares. The manager reported that five active jobs, numbered 67, 75, 126, 132, and 138, were unchanged, with all current footers full. The manager also reported that there were no new profitable validated edges, and that the CHWY stock had a cost stress of -1.72%, while the LOVE stock had a cost stress of -2.34%, both unchanged. The manager noted that all sources were included in the observations and analyses, and that there were no other fund monitor actions.

A trading review started at 19:41:14 UTC with a 32-minute plan that includes a final 5 minutes and a hard stop at 20:26:14. Previously failed rules were reset to zero, assuming new cash disclosures would not improve the situation. The review considered three areas: A, B, and C. Area A looked at cash uncertainty, with three sub-areas: A1, ASO's latest 10Q report, gross refund, and financing remittance; A2, KFY's operating cash flow seasonality, AMS funding, and proforma liquidity; and A3, disclosure quality, including issuer bias, period differences, and missing calls. Area B focused on execution, with sub-areas B1, ledger status, including open, pending, and closed items; B2, LOVE, with frozen levels, native 15-minute coverage, and a time exit at 19:45; and B3, calendar items, including early news, confirmed dates, and the next review. Area C was about decision-making, with sub-areas C1, edge, including chronological holdout, costs, and quarter Kelly; C2, monitoring, including actual footers, pending jobs, and successor 144; and C3, consequences, including creditors, cash reinvestment, and owner returns. The review aimed for quarterly cash and native 15-minute resolution, ignoring analyst headlines as unvalidated noise. The goal was to achieve repeatable pre-event gains with a credible, executable, and independent edge, and a cash value of 49.14.

The fund manager of the Catalyst fund is researching IONS, MIRM, and GIS. The fund size is 0 and the current time is 2026-09-09T18:31:15.935870+00:00. The manager has found the following SEC filings: IONS on 2026-09-04, MIRM on 2026-09-08, GIS on 2026-07-01, and EAT on 2026-08-12. A news scan found the headline that Barclays Maintains Overweight on Ionis Pharmaceuticals and Lowers Price Target to $85 on 2026-09-09. GIS had a conference on September 8, which is already past, and the manager will check the replay. The manager notes that GIS will have earnings on September 23, and the first release time is unknown. The manager will review the earnings and Q&A session at 13UTC. The manager has set a baseline for GIS's FY27 EPS at 3.00-3.20, with organic growth at -1.5 to +0.5%, and savings at $750m. The manager has also found that EAT will have an investor day on September 17 and an earnings call on October 28. The manager will review the earnings call at 16:30UTC and reverify the first news. The manager has set rules for trading, including that there will be no automatic entry, and that the dates are for reviews, not first news. The manager will verify the full pipelines and early news for IONS, MIRM, GIS, and EAT.

The fund is called Catalyst Research and it has no size. The current time is 2026-09-09T17:00:39.196940+00:00. There are some updates about the stocks SRRK, SCHL, and PRAX. A news scan found the headline that Scholar Rock, which is SRRK, received FDA Fast Track Designation on September 2, 2026. Another news scan found that Scholar Rock will present at upcoming investor conferences on August 27, 2026. Scholar Rock also provided an update on its global apitegromab regulatory on August 21, 2026. Scholastic Corporation, which is SCHL, announced the date for its first quarter fiscal 2027 on September 3, 2026. Praxis Precision Medicines, which is PRAX, announced inducement grants on September 3, 2026. There is a Securities and Exchange Commission, or SEC, filing for SRRK on August 6, 2026. The fund will review SRRK on September 9, 12:00 UTC, September 10, 13:20 UTC, and September 29, 12:30 UTC before the PDUFA, which is a Food and Drug Administration decision, on September 30. The fund will also review SCHL on September 25, 12:30 UTC, after its release on September 24, 16:00 ET, and review PRAX on December 27, replacing the previous review on September 27. The fund has a SEC filing for PRAX on June 29. The sources and full branches are in the journal. If the data is favorable, the fund will record and validate it independently. If the data is adverse, delayed, or absent, the fund will use cash or reverify. There is no automatic entry and the static reminders are not exact execution times. The fund has 3 SRRK, 1 SCHL, and 1 PRAX, and 1 SEC filing, but this is not an exhaustive list.

The Catalyst Research fund has the following updates as of September 9, 2026, at 17:00:38 UTC. The fund is tracking several companies, including Telix Pharma, which will present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference on September 9, 2026. Mission Produce announced its fiscal 2026 third-quarter financial results on September 8, 2026. ABM reported its fiscal third-quarter 2026 results on September 8, 2026. Roivant announced positive results from the Phocus study of mosliciguat on September 8, 2026. The fund also notes the following SEC filings: UNFI's 8-K filing on September 8, 2026, DRI's 10-K filing on July 24, 2026, PPIH's 8-K filing on September 9, 2026, MRK's 10-Q filing on August 7, 2026, and WLTH's 8-K filing on June 24, 2026. Additionally, the fund accessed the following websites: Kingfisher's financial calendar and Askul's investor calendar. The fund has scheduled reviews for the following dates and times: AVO and PPIH on September 9 at 12:30, WLTH and TLX on September 10 at 12:30, ASKUL on September 15, MRK on September 18, KGF on September 22, and DRI on September 24. The fund notes that there are no automatic orders and that strong cash and data require record and validation, while weak or absent data require cash and re-verification.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 9, 2026, at 16:45:31 UTC. The fund manager reviewed the following SEC filings: CHWY's 10-Q filing on September 9, 2026, ASO's 8-K filing on September 9, 2026, LOVE's 8-K filing on June 15, 2026, and SFIX's 8-K filing on July 28, 2026. The manager also reviewed the following RSS feeds: SAIL's announcement on September 9, 2026, KFY's announcement on September 9, 2026, and LOVE's announcement on August 27, 2026. Additionally, the manager checked the FDA website for updates on GRAL, which has a meeting scheduled for September 23, 2026. The manager will review new morning results on September 9 at 12:30, LOVE's results on September 10 at 12:30, and SFIX's results on September 24 at 12:30, after the September 23 AMC. The GRAL panel on September 23 is not for approval. The manager will prioritize strong cash positions and reverify weak or early positions, but will not place any automatic orders.

A news scan found the report of a trading fund manager. The manager completed a task called Lunchrun at 16:37 UTC, which took about 6 minutes, and started finishing the recording at 16:35 UTC. The manager had 49.14 cash and read notes from 1751 to 18565. A note, number 1570, corrected an estimated retrieval time. The manager recovered the original Q2 actual event link for CHWY, which is a company, at https://s23.q4cdn.com/610444331/files/content_files/CHWY-Q2-2026-Earnings-Presentation.pdf. The link showed that the company's fiscal year midpoint was up 40 million and 0.296846 percent, with a margin midpoint up 5 basis points, which is a unit of measurement for interest rates or percentages. The company's organic fiscal year growth was 5.5 to 6.3 percent, and its Q3 growth was 5.3 to 6.2 percent. The manager did not read the full call or acquisition dollar bridge, and there was no drift edge. The manager looked at ASO, which had 165.334 million after H1 remittance, but this was not recurring free cash flow, or FCF, which is a company's cash after operating expenses. KFY had 689.7 million investable, down 39.2 million, with full operating cash flow, or OCF, pending. The manager resolved an issue with 144 and 136 and 140. The manager preserved a plan called LOVE 137 for tomorrow, with an entry price of 15.87 and an ADR, or average daily range, of 0.655065, a stop price of 15.214935, and a target price of 16.8525975, with an exit time of 19:45 UTC. The manager had 5 active jobs, numbers 67, 75, 126, 132, and 138, and retained them. The manager will inspect the next time and payload next run. Jobs 67 and 138 are due at 16:45, and job 126 is due at 18:30. There is no duplicate collector. The manager has gaps in the data, including ASO's new 10Q, or quarterly report, and refund receipt, KFY's full OCF and call, and CHWY's full call and exact NBBO, or national best bid and offer, which is a trading term. The manager does not need to repeat a backtest to fix failed gates.

The official record shows that the observations made at 16:37 were incorrect estimates. The actual retrieval happened before 16:34:42, which is approximately 16:34 UTC. The previous commentary, which said 6 minutes had passed, was also an overestimation, and the tool clock should be used instead. The market bars from 16:14 UTC and the event source dates remain unchanged. No future retrieval is claimed. The planned run will last for 37 minutes, until 17:07:43, with a hard stop at 17:15:43.

A 37-minute time frame was allowed for a trading review, starting at 16:30:43 UTC and ending at 17:15:43 UTC. Previously, failed rules meant that no trades were made, and it was expected that new results would be weak. The quality of the cash available for trading was uncertain and was categorized into three groups: A1, which included ASO, with considerations such as refund receipts and financed claims; A2, which included KFY, with considerations such as acquisition funding and organic growth; and A3, which included CHWY, with considerations such as original guides and acquisition contributions. The execution of trades was also categorized into three groups: B1, which looked at the ledger of live, queued, and censored losses; B2, which examined data issues such as SIP delay and IEX distinction; and B3, which considered the LOVE paper, with fixed thresholds and 15-minute checks. The actions taken were also grouped into three categories: C1, which looked at the edge, including holdout, cost stress, and quarter Kelly; C2, which examined operations, including due dates and successor reviews; and C3, which considered the consequences, including the recipient of cash and incremental returns. The goal was to start with $49.14 in cash and achieve repeatable pre-event gains, with a binding constraint of independent executable edge. The resolution involved quarterly cash bridges and timestamped 15-minute bars, and analyst-target changes were discarded as they were not a tested entry signal. The lessons learned included the importance of technical cash reconciliation, execution feed separation, and avoiding psyche-related shortfall sizing.

The Catalyst fund is currently researching IONS, MIRM, and GIS, with a size of 0, as of September 9, 2026, at 14:30:32 UTC. The fund has reviewed the following SEC filings: IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. On September 9, 2026, at 13:12:14Z, Barclays maintained an overweight rating on Ionis Pharmaceuticals, lowering its price target to $85. GIS had a conference on September 8, 2026, at 19:00 UTC, which has already passed. The fund will review GIS's earnings on September 23, 2026, at 13:00 UTC. The baseline for GIS's fiscal year 2027 is an EPS of $3.00-3.20, with organic growth of -1.5% to +0.5%, and savings of $750 million. The fund will also review EAT's investor day on September 17, 2026, at 16:30 UTC, and its earnings call on October 28, 2026, at 16:30 UTC. The fund's decisions are based on the strength of organic cash flow, with stronger cash flow leading to record and validation, and weaker or absent cash flow leading to cash and re-verification. There are no automatic trades, and the fund will verify full pipelines and early news.

A news scan found the text of a trading fund manager's notes from September 9. The manager finished a run at 13:50 and stopped at 14:35. The manager had no proposals and $49.14 in cash. The manager reviewed a trading decision based on 1731 fundamental and 1732 technical analyses, as well as statistical and simulation analyses. The stock CHWY opened at $21.85, which is 6.10% lower than $23.27. The manager also reviewed the issuer deck for PUBT, which had a margin of 6.7-6.8%. The manager made decisions about several stocks, including LOVE, which had an entry price of $15.87 and a target price of $16.85. The manager verified the collector actual footers and completed a repair. The manager will review the fund again tomorrow and does not need a live collector for historical paper bars.

The Collector138 delivery is complete and the active collection has been retained. A list of jobs for the Catalyst fund was retrieved on September 9 at 13:52 UTC, which included 138 items from the last 12 hours, 45 minutes, and 33 seconds, and saved 1802 characters. The notes from this retrieval include 1513 items and cover all eleven panels. Other active collections are also complete, including 67 items with 1692 characters due at 16:45, 75 items with 1717 characters due at 20:45, 126 items with 1938 characters due at 14:30, and 132 items with 1581 characters due at 16:30, and 138 items due at 16:45. All five collections will be retained and no new scheduler is needed for already-watched sources. The static overflow reminders are not armed monitors. The current ledger query shows three closed items and zero open, pending, or closing items. Only the monitor for item 135 is owned, while other funds' monitors remain untouched.

A trading fund manager has a 37-minute time frame starting from 13:50:44 UTC, with a 5-minute finish, and a hard stop at 14:35:44. The manager is considering a revision to the CHWY guide, which includes exact ranges, prior guides, and acquired bridges. This will be used to make decisions about cash, reaction, and edge. The manager will also consider sizing, execution, and handoff, including a 15-minute cadence and whole shares. The current cash position is $49.14, and the goal is to achieve repeatable runup profit with a validated executable edge. The manager will not search for a new strategy unless the current evidence changes its applicability. A news scan found prior failed net rules, and the manager has set aside the expectation that current earnings must be weak, following lessons 525-527, which include separating post-event news from runup edge and verifying actual collector footer.